Cargando…

Effect of HK2, PKM2 and LDHA on Cetuximab efficacy in metastatic colorectal cancer

Although hexokinase (HK) 2, pyruvate kinase muscle (PKM) isozyme 2 and lactate dehydrogenase (LDH) A predict the efficacy of medicines in various solid tumors, their ability to predict the efficacy of cetuximab in metastatic colorectal cancer (mCRC) remains unclear. mCRC patients with pathological s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Haohua, Peng, Roujun, Chen, Xiuxing, Jia, Rui, Huang, Chunyue, Huang, Yuanyuan, Xia, Liangping, Guo, Guifang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840691/ https://www.ncbi.nlm.nih.gov/pubmed/29552193 http://dx.doi.org/10.3892/ol.2018.8005

Ejemplares similares

First-line cetuximab improves the efficacy of subsequent bevacizumab for RAS wild-type left-sided metastatic colorectal cancer: an observational retrospective study
por: Liu, Shousheng, et al.
Publicado: (2020)

Efficacy and mechanism of combination of oxaliplatin with PKM2 knockdown in colorectal cancer
por: Yin, Chenxi, et al.
Publicado: (2020)

PPARγ contributes to PKM2 and HK2 expression in fatty liver
por: Panasyuk, Ganna, et al.
Publicado: (2012)

Interactome analysis reveals that lncRNA HULC promotes aerobic glycolysis through LDHA and PKM2
por: Wang, Chunqing, et al.
Publicado: (2020)

Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data
por: Guo, Guifang, et al.
Publicado: (2018)

Metabolic Alterations Caused by Simultaneous Loss of HK2 and PKM2 Leads to Photoreceptor Dysfunction and Degeneration
por: Weh, Eric, et al.
Publicado: (2023)

MiR-489-3p Reduced Pancreatic Cancer Proliferation and Metastasis By Targeting PKM2 and LDHA Involving Glycolysis
por: Zhang, Dan, et al.
Publicado: (2021)

Expression of HK2, PKM2, and PFKM Is Associated with Metastasis and Late Disease Onset in Breast Cancer Patients
por: Ishfaq, Mehreen, et al.
Publicado: (2022)

Inflammation-based markers can predict the prognosis of geriatric patients with metastatic colorectal cancer receiving first-line chemotherapy
por: Guo, Guifang, et al.
Publicado: (2019)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

PKM2 and cancer: The function of PKM2 beyond glycolysis
por: DONG, GAOCHAO, et al.
Publicado: (2016)

Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells
por: Kudryavtseva, Anna V., et al.
Publicado: (2016)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes
por: Guo, Guifang, et al.
Publicado: (2019)

Cetuximab treatment in a patient with metastatic colorectal cancer and psoriasis
por: Neyns, B., et al.
Publicado: (2008)

PKM2 in carcinogenesis and oncotherapy
por: He, Xia, et al.
Publicado: (2017)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

PKM2 promotes reductive glutamine metabolism
por: Liu, Miao, et al.
Publicado: (2018)

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
por: Jehn, C F, et al.
Publicado: (2012)

Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer
por: Goldberg, Richard M, et al.
Publicado: (2018)

Cost-effectiveness of cetuximab and panitumumab for chemotherapy-refractory metastatic colorectal cancer
por: Carvalho, Adriana Camargo, et al.
Publicado: (2017)

Efficacy of Liver Chemoembolization after Prior Cetuximab Monotherapy in Patients with Metastatic Colorectal Cancer
por: Szemitko, Marcin, et al.
Publicado: (2023)

Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer
por: Queralt, Bernardo, et al.
Publicado: (2016)

Sam68 promotes aerobic glycolysis in colorectal cancer by regulating PKM2 alternative splicing
por: Zhao, Jing, et al.
Publicado: (2020)

EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2
por: Chen, Shengnan, et al.
Publicado: (2020)

EGFR-PKM2 signaling promotes the metastatic potential of nasopharyngeal carcinoma through induction of FOSL1 and ANTXR2
por: Chen, Shengnan, et al.
Publicado: (2020)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Longterm effects of palliative local treatment of incurable metastatic lesions in colorectal cancer patients
por: Yang, Qiong, et al.
Publicado: (2016)

Genetic and immune factors underlying the efficacy of cetuximab and panitumumab in the treatment of patients with metastatic colorectal cancer
por: Krawczyk, Paweł Adam, et al.
Publicado: (2013)

Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer
por: Tintelnot, Joseph, et al.
Publicado: (2022)

A feedback loop between NONHSAT024276 and PTBP1 inhibits tumor progression and glycolysis in HCC by increasing the PKM1/PKM2 ratio
por: Li, Yuwei, et al.
Publicado: (2022)

CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy
por: Mallardo, Domenico, et al.
Publicado: (2023)

LDHA Desuccinylase Sirtuin 5 as A Novel Cancer Metastatic Stimulator in Aggressive Prostate Cancer
por: Kwon, Oh Kwang, et al.
Publicado: (2023)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study
por: Tanioka, Hiroaki, et al.
Publicado: (2018)

Copine 7 promotes colorectal cancer proliferation through PKM2 interaction and MAPK signaling pathway
por: Yu, Tianwen, et al.
Publicado: (2023)

PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer
por: Sfakianaki, Maria, et al.
Publicado: (2020)

N(6)-methyladenosine-mediated LDHA induction potentiates chemoresistance of colorectal cancer cells through metabolic reprogramming
por: Zhang, Kun, et al.
Publicado: (2022)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_0h3iv99kjdarcumd057iaifvr2